The Massey Cancer Center is a matrix center located at Virginia Commonwealth University, whose mission is to provide comprehensive, cancer-focused basic, clinical, and population research, clinical services, outreach, and education to the State of Virginia and the nation. The major goals of the Cancer Center are 1) to facilitate high-quality basic, clinical, and population-based research focused on the cancer problem and 2) to promote interdisciplinary and transdisciplinary collaborations among the scientific programs and members of the Cancer Center and translate findings into more effective interventions for cancer prevention and treatment. During the last project period, NCI annual total cost funding for Cancer Center members increased from $15,777,576 to $18,011,992, and total peer-reviewed funding from $33,125,861 to $38,016,473. During this period we expanded translational and clinical research activities, increased high impact cancer-focused research, and increased transdisciplinary research. Major goals for the next grant period are to further enhance our translational-clinical research activities, increase the depth and scope of collaborative programmatic research, and intensify our research focus on the problems of health care disparities among racial, ethnic, and other underserved populations. Research activities of the Massey Cancer Center are earned out through five research programs: Cancer Cell Signaling, Cancer Molecular Genetics, Cancer Prevention and Control, Developmental Therapeutics, and Radiation Biology and Oncology. The translational programs include both basic research and either clinical/translational or applied population research so as to facilitate transdisciplinary collaboration and rapid implementation and dissemination of research findings. In order to provide support for the predominantly peer-reviewed research base of the scientific programs, the Cancer Center supports nine shared resources: Clinical Research;Biostatistics;Flow Cytometry;Biologic Macromolecule;Behavioral Measurement;Structural Biology;Transgenic/Knockout Mouse;Cancer Research Informatics and Services;and Tissue and Data Acquisition and Analysis. This application requests continuation of CCSG funding to provide partial support for these shared resources as well as for senior leadership, program leadership, administration, staff investigators, protocol-specific research, program planning and evaluation, protocol review and monitoring, data and safety monitoring, and developmental funds, which are necessary to facilitate and stimulate transdisciplinary cancer research and translation throughout the Cancer Center.

Public Health Relevance

The mission of MCC is to serve Virginia and the nation as an internationally recognized comprehensive research and treatment center dedicated to improving the quality of human life by eliminating suffering and death through development and delivery of more effective means for the detection, treatment, prevention, control and ultimate cure of cancer. The core of this mission is to facilitate interdisciplinary and transdisciplinary cancer research so as to harness the considerable intellectual talent and scientific resources of VCU and focus them on solving the nation's cancer problem.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016059-32S1
Application #
8710403
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ptak, Krzysztof
Project Start
1978-12-01
Project End
2017-04-30
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
32
Fiscal Year
2013
Total Cost
$43,749
Indirect Cost
$15,061
Name
Virginia Commonwealth University
Department
Biochemistry
Type
Schools of Medicine
DUNS #
105300446
City
Richmond
State
VA
Country
United States
Zip Code
23298
Lochmann, Timothy L; Powell, Krista M; Ham, Jungoh et al. (2018) Targeted inhibition of histone H3K27 demethylation is effective in high-risk neuroblastoma. Sci Transl Med 10:
Quinn, Bridget A; Deng, Xiaoyan; Colton, Adrianne et al. (2018) Increasing age predicts poor cervical cancer prognosis with subsequent effect on treatment and overall survival. Brachytherapy :
Das, Swadesh K; Pradhan, Anjan K; Bhoopathi, Praveen et al. (2018) The MDA-9/Syntenin/IGF1R/STAT3 Axis Directs Prostate Cancer Invasion. Cancer Res 78:2852-2863
Mohan, Abhinav; Schlue, Kyle T; Kniffin, Alex F et al. (2018) Spatial Proliferation of Epithelial Cells Is Regulated by E-Cadherin Force. Biophys J 115:853-864
Farkas, Daniela; Thompson, A A Roger; Bhagwani, Aneel R et al. (2018) Toll-like Receptor 3 is a Therapeutic Target for Pulmonary Hypertension. Am J Respir Crit Care Med :
May, Peter; Garrido, Melissa M; Del Fabbro, Egidio et al. (2018) Does Modality Matter? Palliative Care Unit Associated With More Cost-Avoidance Than Consultations. J Pain Symptom Manage 55:766-774.e4
Floros, Konstantinos V; Lochmann, Timothy L; Hu, Bin et al. (2018) Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy. Proc Natl Acad Sci U S A 115:E2594-E2603
Warthan, Michelle D; Washington, Sonya L; Franzese, Samone E et al. (2018) The role of endoplasmic reticulum aminopeptidase 2 in modulating immune detection of choriocarcinoma. Biol Reprod 98:309-322
Booth, Laurence; Roberts, Jane L; Rais, Rumeesa et al. (2018) [Neratinib + Valproate] exposure permanently reduces ERBB1 and RAS expression in 4T1 mammary tumors and enhances M1 macrophage infiltration. Oncotarget 9:6062-6074
Rizzo, Juliana; Colombo, Ana C; Zamith-Miranda, Daniel et al. (2018) The putative flippase Apt1 is required for intracellular membrane architecture and biosynthesis of polysaccharide and lipids in Cryptococcus neoformans. Biochim Biophys Acta Mol Cell Res 1865:532-541

Showing the most recent 10 out of 586 publications